Failure of colchicine to reduce inhaled triamcinolone dose in patients with asthma☆☆☆★
| Autor: | Andrea Buchmeier, Phillip Corsello, Karen B. Schmaling, Harold S. Nelson, Kenneth B. Newman, Ulysses G. Mason |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Triamcinolone acetonide medicine.drug_class Immunology Familial Mediterranean fever Triamcinolone Severity of Illness Index Drug Administration Schedule Gout Suppressants chemistry.chemical_compound medicine Humans Immunology and Allergy Colchicine Urticarial vasculitis Glucocorticoids Transaminases Aged Asthma Platelet Count business.industry Interstitial lung disease Adrenergic beta-Agonists Immunoglobulin E Middle Aged medicine.disease Dermatology Blood Cell Count Respiratory Function Tests Gout chemistry Anesthesia Corticosteroid Female business medicine.drug |
| Zdroj: | Journal of Allergy and Clinical Immunology. 99:176-178 |
| ISSN: | 0091-6749 |
| DOI: | 10.1016/s0091-6749(97)70092-7 |
| Popis: | In recent years there has been significant interest in alternative antiinflammatory agents in the treatment of asthma. However, many of these medications are limited by modest efficacy, toxicity, or cost. Colchicine is an inexpensive and safe medication, which has unique antiinflammatory properties. Although traditionally used to treat gout, it has also been used in various inflammatory disorders such as familial Mediterranean fever] Behcet's syndrome, urticarial vasculitis, 2 and interstitial lung disease. 3 Prior studies have suggested a potential role for colchicine in the treatment of asthma. 4-7 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect